Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
PCM111, good post find—-the mkt has had an increased reporting frequency regarding AI, glad to see CH recognized...
(I’ve read this article below few days ago, what’s exciting is to see the “different” media sources that are posting)...Also, this is for NEWBIES...& those who have not seen!!! Tic toc tic...
Comprehensive Analysis on Healthcare Artificial Intelligence Market with Key Players: AiCure, Atomwise, Cyrcadia Health, Lifegraph Ltd, Welltok, Inc.
...skip paragraphs
Company profiled in this report based on Business overview, Financial data, Product landscape, Strategic outlook & SWOT analysis:
- AiCure
- Atomwise
- Cyrcadia Health
- Lifegraph Ltd
- Welltok, Inc.
- Enlitic
- Insilico Medicine, Inc
- Apixio
- Butterfly Network, Inc.
- SOPHiA GENETICS
- iCarbonX
- Modernizing Medicine
- Sensely
- Zebra Medical Vision Ltd
- Pathway Genomics Co
...skip paragraphs
Medical imaging and diagnosis should witness more than 40% growth to surpass USD 2.5 billion by 2024. Rising application of artificial intelligence in medical imaging has improved cancer tumour diagnosis at a very early stage compared to radiology. It utilizes deep learning techniques providing extraordinary performance for pattern recognition leading its way to become a game changer in the imaging and diagnosis industry.
Read more: http://m.digitaljournal.com/pr/4037951#ixzz5YLjpcySL
https://www.whatech.com/market-research/industrial/532554-global-artificial-intelligence-ai-in-healthcare-market-detailed-in-new-research-report
old/new post it we have new blood coming in, let them see what is going on.
many are lazy and don't want to search through previous post. I fully intend on repeating post for the next month. I'm sure at the displeasure of some of our negative residents, ask me if I give a damn my dear girl !!
Well since we r in a lull period, who’s ready for Christmas or any other holiday?
But, with that said some of u have commented on a possible Asia & USA launch simultaneously thank you...
(Sitting here this am hyped up on my favorite legal drug caffeinated coffee, something was really bothering
me like an itch u can’t reach...USA/Asia simultaneously getting the iTBra was it possible ???
So time to dig deeper, That’s when I found the KABC June 8, 2017 ABC news interview with Rob Royea. He clearly states the intent
to launch the iTBra in Asia & the USA simultaneously. Well that was to be in 2018...that’s ok, I’ll take 2019.
Is the Cyrcadia Health website relaunch really just being held back until the Asia launch, afterall it’s quite simple
to rebuild a website these days & put it back up, then when Asia launches update it, front page news, press releases, etc.
Could it be, could it be that they Really are going to launch simultaneously & want the updated website to announce this, along with the usual press releases, etc. So thanks goes to my fellow investors or whomever said there might be a simultaneous launch, because I wouldn’t have seen the KABC interview... “Ask, and it shall be given you; seek, and ye. shall find; knock, and it shall be opened unto you: 8 For every one that asketh receiveth; and he that seeketh.” Matthew7:7-8
Tic toc tic toc...
.05–.07 on launch, settling back & then secondary rebound possibly higher (it’s the only way into the game
& the anny Up won’t be cheap just my opinion like it or hate it !) If news of a possible USA launch soon, then strap in & hold on...
LLBO Est PPS .22
Lifeline Biotechnologies
USA/Asia valuation, not including Europe, Russia, Australia, S America...
(The .22 takes into consideration of Lifelines 47% equity share of Cyrcadia Incorporated as well as percentage ownership of Cyrcadia Asia & Cyrcadia Asia’s stock ownership of Cyrcadia Health.)
Article for “”NEW”” investors. iTBra technology, mkt, etc.
https://medium.com/@maciejkranz/with-early-cancer-detection-iot-saves-more-than-money-it-can-save-lives-a29c03be2860
Well back under revision again but their server was down for a good hour is one
“The iTbra™ device is not available for sale or distribution in the United States”, interesting this pops up on
4search.com, under Cyrcadia Health website link—it use to say, “Cyrcadia Health -Please check back soon to see our new website. Contact us for more information.”
Also, CH data link cannot be established...could it be about to relaunch...???
The drums beat louder !
LLBO Est PPS .22
Lifeline Biotechnologies
USA/Asia valuation, not including Europe, Russia, Australia, S America...
(The .22 takes into consideration of Lifelines 47% equity share of Cyrcadia Incorporated as well as percentage ownership of Cyrcadia Asia & Cyrcadia Asia’s stock ownership of Cyrcadia Health.)
——Details in previous post...#27131
Lifeline Biotechnologies
PPS Est .22 Cents
LLBO
(It’s a journey so stay with me)
EBITDA PPS valuation for small/midsize CO’s. is 5-7x earnings. EBITDA(Earnings before interest taxes depreciation and amortization)
Let’s Compute PPS using the above commonly used securities formula:
Cyrcadia Health CH
Cyrcadia Asia
CA
~40 Million Mammograms not including other breast screenings per yr USA, not including the rest of the world.
But, (Asia breast cancer screening market size is expected to cross over US $4 Billion by 2022, @ US ~avg cost $100ea this equals 40 million Asian breast screenings annually). iT Bra to begin Asia Dist this January. If CA iTBra gets 10% of that Mkt ((current female population of Asia is 2,550,000,000
BILLION (say what!)
49.6 % of women population is urban, median age is 31—4Mil iTBras no problem)) = 4,000,000mil users x $150= $600Mil revenue ((CA iTBra-12 scans uploaded per yr for a total annual cost of ~$150 info provided by CA)) & avg gross EBITDA profit of 45% (600x.45)=
$270Mil at 5X that profit =(270x 5)= $1.350 Billion Cyrcadia Asia value).
USA value is equivalent given equal market comparison, so (1.35+1.35)=
$2.7 Billion combined CH/CA value using EBITDA standards @ 5x earnings (Not 7x), & most recent Co. data released.
(That’s the big picture, & the one I believe the Mkt will react to given my past experience)
So LLBO PPS:
LLBO owns 47% of CH ...So
CH Val including CA% ownership (per Fin. Info released & some Algebra is
1.35Bil CH +103Mil CA = $1.453Bil total CH value, so LLBO .47 x 1.453=
$683 Mil LLBO value.
Stay with me now
So 683/3.1bil shares O/S =
LLBO stock price of $.22 PPS USA & Asia only.
(No S Amer., Europe, Russia, Australia...)
Total Company & affiliates est value
CH $26 PPS ~27Mil shares O/S
CA $51 PPS ~34Mil sharesO/S
LLBO $.22 ~3.1
Bill shares O/S
Above numbers only include USA & Asia (no Europe, Russia,etc) the world wide market expenditure on breast cancer is ~ One “Trillion” US Dollars $1 Trillion
(Now obviously something as big as breast cancer & the need for alternative solutions, not to mention the —-“only” ——present way to get into the upcoming product launch is “LLBO stock” & don’t take that lightly.
Share price could fluctuate to higher levels on speculative value & it’s my personal opinion they will. I leave it up to the market as to where speculative PPS goes ?
(iTBra has FDA clearance)
(All of the above information was derived by using readily available breast cancer research information. Cyrcadia Inc released public financial info., iTBra target selling prices recently released & info such as CH CA % ownership, CA issued shares to CH, CA owned shares of CH, LLBO CH share holdings, applied mathematics & other info.
As PPS valuation is never an exact science I did my best to use hard data with as little speculation as possible IE: For instance what woman would not want to beat 1:8 odds of getting invasive breast cancer? Think of how many lottery tickets you’d buy with those odds. Thus my speculative 10% of breast screening market for PPS valuation ! (Hell, don’t like 10% use 2% still a hell of a PPS)
Also, Keep in mind the iTBra is not going to reduce the breast screening market
I merely use breast screening & statistics as a fixed point as it’s hard data.
GLTA
Cyrcadia, Inc. – 2017 Year End and 2018 Look Forward Newsletter
| Feb 21, 2018 |
——Exert——
“The intent is to launch into both the consumer and Over the Counter (OTC) markets almost simultaneously with the clinical markets. Thus far, indications are favorable for this approach and we will be meeting directly with the FDA in the months to come, declaring our intent. We will report again on the meeting outcomes once definitive. Moreover, CI will pursue a Modified 510(k) through the FDA enabling the rapid expansion of the clinical markets. This does not preclude us from going to market with our existing 510(k), Class II clearance (see the NFJ position above), but will certainly enhance our visibility and buy-in from the medical/clinical community.
On behalf of the Cyrcadia, Inc. team, we thank you for your support as we bring this life saving technology to market. We will make every effort to ensure timely and profitable delivery of CI’s technology to the U.S. market and rest of world outside of the territories covered by CA.
Sincerely,
Matt Benardis
CEO
Cyrcadia Health
“How brands are using AI and VR to boost health care and predict trends”
BY DIANE YOUNES
20 SEP 2018
——-Exerpt——
Lau is keeping a close eye on a specific start-up, which is using AI to link fashion and health care.
For Asian women, our biology and size means that the current standard of mammography is not as accurate as it needs to be.
“What Cyrcadia is doing with AI and breast cancer detection is a game-changer.”
Have a good Thanksgiving &
HO HO HO Merry Christmas, Happy Holidays & Happy Any other Holiday Celebrated by all ...to all !
:>)And to the negatives out there, piles of smiles :)
GfA only advice I have
A pig is a pig, with or without wings. Same goes for highly speculative penny stocks.
Unpredictability, lack of validated financial ratios, lack of PROVEN product, & time value
all hold down PPS of these companies.
But that is the beauty of them, the speculative investor can be rewarded 10-30-50 plus
times over investment...unfortunately it is simply the nature of these animals to stay grounded
Until they grow wings and fly.
Holding 1.9 million shares LLBO until death we part !
Is it just me or did the “Forward Looking Press Release”—just appear at the top of the LLBO page ???
Interesting (my previous post had excerpts from the original FULL PRESS RELEASE !!!
Tic toc tic toc tic toc tic toc...$$$
PPS- Meads right on (But, I believe 47% ownership of CH)
Angie Lau award winning former presenter at Bloomberg Television now leads her own team at Narramur, a cutting-edge communications advisory company focused on narrative and technology.
(She says: “Cyrcadia Asia is about to launch its first product Jan 2019 called the IT bra in Hong Kong and globally. It is the first wearable technology that will simply change the course of breast cancer detection forever.)
Breast Cancer.org
About 1 in 8 U.S. women will develop invasive breast cancer over the course of her lifetime. ( how many lottery ticket would you buy those odds)
“iTBra it’s the beginning of a revolution … for a women in the comfort of home, to get new information about breast cancer to the physician.”
There are only three things I am certain of in life-Taxes, Death & LLBO going up.
PPS speculation, well we will find out.
Marketing Intent & FDA Class11 Newsleter: (sure we’ve seen it, but I think it answers some current questions-only posted parts of it
if want to read all then google the title)
Cyrcadia, Inc. – 2017 Year End and 2018 Look Forward Newsletter
by admin | Feb 21, 2018 | News | 0 comments
“The intent is to launch into both the consumer and Over the Counter (OTC) markets almost simultaneously with the clinical markets. Thus far, indications are favorable for this approach and we will be meeting directly with the FDA in the months to come, declaring our intent. We will report again on the meeting outcomes once definitive. Moreover, CI will pursue a Modified 510(k) through the FDA enabling the rapid expansion of the clinical markets. This does not preclude us from going to market with our existing 510(k), Class II clearance (see the NFJ position above), but will certainly enhance our visibility and buy-in from the medical/clinical community.”
“As previously noted, the first clinical market entries are likely to be with insurance partners working through CA in Asia (and by extension, CI in the U.S.). CI will also launch a lead out pilot in the U.S through Evidation Health (see evidation.com) and its affiliates, Dignity Health and Kaiser Permanente. Evidation, associated with Stanford University and funded by GE Ventures and others, evaluates how the evolution of digital health and wearables can affect change from a care and insurance perspective in the U.S. Through Evidation, the pilot launch will involve a nominal number of subjects with a rapid pace of subscription and validation to both publish and allow leading healthcare providers, insurers and key opinion leaders to observe the value and marketability of the CI solution. This relationship and process provides rapid exposure to the caliber of the business partners and associates of Evidation that would otherwise take years to achieve. These relationships are key to expediting mandates to participants of the insurers and healthcare networks without CI’s need for significant staffing and fundraising to develop an internal salesforce within CI.”
“Our priority now is to finalize and implement our marketing plan enabling the ramp up of sales as soon as possible in 2018 upon product delivery.”
“On behalf of the Cyrcadia, Inc. team, we thank you for your support as we bring this life saving technology to market. We will make every effort to ensure timely and profitable delivery of CI’s technology to the “U.S. market”and rest of world outside of the territories covered by CA.”
Sincerely,
Matt Benardis
CEO
Cyrcadia, Inc
(I think that is pretty clear)
Yaro nice find, E 7 2 well said I’ll bet your spot on...
Well well we’ll looks like Cyrcadia Health/Asia are feeling a little pressure...
Wonder why that is, how about women in the US want the iTBra 1:61 chance of
invasive breast cancer odds, why not try to beat em...?
But, your questions r spot on why did CA respond & not CH, several reasons:
1) CH website is currently under revision, so obviously the Not for sale in US AT THIS TIME statement
Can’t be posted there...
2) There has been much push threw going on with various contact sites- twitter, Facebook, direct email to quite a few large organizations, Doctors,AARP, Cancer causes, etc., recently (Rob Royea product release date/pricing live interview with HKIBN,
etc etc.) May have created many inquiries??? —-Everyone has done their job—-
Mead may be spot on with CH website re-launch & USA iTBra FDA OTC approval since they
already have FDA Class11 approval (& if anyone says they don’t have FDA Class11 “ go jump in a lake & hold your breath” or
do some research.) I added in the FDA Over the Counter approval because that is exactly what they
are working on with the FDA. Of course if indeed this was the case, I’m not sure if the ticker could move fast enough.
But, one thing I am beyond certain of is when the CH website reopens the iTBra will have launched SOMEWHERE ?
Conclusion: Let’s face it the iTBra is coming out of the cage, and everyone wants to see the Tiger!!! Tic tic tic...
“There is thus a large need for early detection options.” Tic tic tic toc...
(Recently while looking at new Valuation, I found this 2 1/2 times larger than I thought $$$)
Breast cancer screening: growing worldwide
Jul 12, 2017
~250,000,000 Million...Breast cancer screenings Worldwide. ((Say What!!!))
“Breast cancer is the most common cancer in women worldwide, and the number of women affected continues to increase.1 There is thus a large need for early detection options. While breast cancer occurs extremely frequently in industrialized countries with Western lifestyles, the largest increase in disease rates is expected in less developed countries.2 By 2018, the total number of women worldwide who qualify for breast cancer screening could reach around 250 million.3
A driving force behind this development is the aging of the world population. It is well known that the probability of developing breast cancer increases with age. Also, a rising standard of living with greater educational opportunities for women results in later births and shorter lactation periods. This leads indirectly to a higher risk of breast cancer due to changing hormonal influences.
China is therefore one of the largest markets for breast cancer screenings, along with the United States, Brazil, Japan, and Germany. China has experienced a rapid increase in disease rates since the early 1990s. Various regional screening programs have been developed in China since then. However, experts do not anticipate nationwide mammography screenings based on Western-style models in the near future. In fact, it is possible that ultrasound screening will play a role, as the procedure offers advantages for Asian women, who tend to have denser breast tissue and small breasts, and often develop cancer at an earlier age.4
While screening services are frequently offered by the private healthcare sector in emerging and developing countries like India, public screening programs are barely affordable in these countries.5 Cultural barriers can also stand in the way of breast examinations for early detection.6
On the other hand, in industrialized countries with organized screening programs, the services are paid for through taxes or by health insurance companies (sometimes with a co-payment from the patient) at predetermined rates. The total cost of the German mammography screening program, which screens around half of the women who are entitled to use the program, amounts to approximately US$200 million to US$250 million per year. That equates to about €70 or €80 per screening mammogram, including double reading, centralized quality assurance, and subsequent assessment examinations.7
((“Paid For by, remember are friends the cheer leaders—Insurane Co’s , as stated in my New Inv Post, also Gov Healthcare will pay—my God Germany alone $ 200 Million annually...& how about Asia, remember World War 2 the sleeping giant-well guess who is waking up Asia!!!
It’s here people, and why LLBO is not launching PPS yet is beyond me as a previous Dean Witter Stock Broker-
BA Acct/Mktg it is beyond me...
Just a lousy $500 inv at this current PPS will most likely return ~$11,000 just at .05 Cents...Speculative reality at it’s best...tic toc tic toc tic toc “Hellooo Is There Anyone Home”.
Wrestler excellent find...yes indeed the day of reckoning is upon us, January target launch will light up news rooms.
E72, hey apologies to my previously posted pricing info & launch date..
Yaro (oh crap forgot other poster), had previously posted the Rob Royea
Asian interviews part 1 & 2 which have the Jan 2019 launch date in part 2 & product pricing on
Part 1 (it’s long)., targeting $100-150 for 12 iTBra uploads $8-12/ea screening...
For those of you that don’t know, These interviews are available on the Cyrcadia Asia website under media, there is other information there as well, but I believe it has been posted...
LLBO iTBra cost & launch Date:
Cyrcadia Health has released pricing on their iTBra home use & upload to AI Cloud-Doctor-Patient analysis. Target of $100-150 total for 12 monthly scan uploads (initially $200-250) With a 1:61 chance of getting invasive breast cancer, Hell I’d buy all the lottery tickets I could with those odds, so don’t u think they’ll sell a few iTBras...my wife sure the hell thinks so...
Asia this “Jan2019 launch”—Family Practitioner, OBGYN, Hospital, etc. The 2nd phase is OTC market mid/late 2019...China 2020, maybe late 2019, same time period for balance of Asia, Australia.
CA is currently working with major Sportswear company to incorporate iTBra tech into sports/athletic Bra-ho ho ho.
(ground control to Major Tom)
The 11th hour...tic toc
Cyrcadia Asia
With the largest database on women's breast cancer worldwide, Cyrcadia Asia uses predictive AI technology for earlier and more accurate breast cancer detection.
The past Investors that I have named in past post, make what we have
invested look like chump change, if they felt deceived the SEC would have
already been contacted...old news.
it appears the gamble has paid off for Cisco and Rob Royea...(excerpt from below article,
& yes I know most have seen these articles, but new folks are peeking in)!
Wearable Tech, Breast Cancer & Cisco
Jan 22, 2018
By Harold Selden:
One might never think that Cisco (Cisco funded the documentary because, "when we see technologies like these arise, we know that if they're very successful at detection, the adoption will be massive. We look across this impact of the IoT trend not just in healthcare but all industries," said Raakhee Mistry, Cisco director of marketing for enterprise networks.) would be involved with wearable tech, never mind breast cancer – but a movie?
Yes, Cisco underwrote a movie: Detected. It is a documentary about an iTBra (#iTBra) and a vision of using Big Data and wearable technology to drastically improve – for less money as well – a method to detect breast cancer early. Before we get to the "why Cisco" part, let’s discuss the technology behind this ground-breaking bra.
(DETECTED iTBra & other iTBra Docus can be viewed on YouTube)
Rob Royea, the CEO and Chairman of Cyrcadia Health, his wife, and the film’s director were the stars of the discussion following Detected’s west coast premier earlier
The film tells the story of a startup that seeks to bring a medical product to market. Rob finally gets a working prototype, and has his wife wear the bra, then upload the data for analysis. In between the nerve-wracking wait for results, along with the inevitable startup travails, the film interleaves stories of breast cancer survivors and, stories of uncomfortable breast screenings.
History
The bra itself is based on older research that showed a difference in dynamic circadian temperature between normal breast tissue and tissue with even small tumors, when sampled at many points. However, that research was impractical to implement: it used custom lab grade thermo probes, and individual analysis of each pattern. Here, the Cyrcadia team went to Israel for a custom design using advanced manufacturing techniques to make custom prototypes with embedded probes throughout the bra. Another group based in Singapore directed creation of custom algorithms that could analyze the collected data in the cloud, and apply machine learning to interpret the data sets.
The Problem
The traditional screening technique for breast cancer – X-ray imaging – is uncomfortable, is not ever close to 100% detection, and does not work well on women with dense breast tissue. X-ray imaging is unavailable to more than 50% of the world’s women, and is extraordinarily uncomfortable. The film showed some women complaining about squished breasts. For those unfamiliar with the procedure, the technique seeks to flatten the breasts in what can only be described as a pancake. Other cancer screening modalities, such as MRI, are even more expensive and limited by availability, or do not have a high detection rate (ultrasound). These techniques are based on the differential reflection of density changes within breast tissue to pinpoint abnormal changes; the iTBra is based on detecting metabolic changes.
Preliminary Results
For the iTBra, the time period necessary to collect valid results was initially 48 hours; that has now been reduced to 12 hours. The Cyrcadia team hopes to get that time down to close to two hours (they have) at about the time the first commercial product is ready for full scale testing. The first roll-out will be in Asia, because of several factors: less entrenched traditional screening, lack of general availability of breast cancer screening, and lack of suitable screening: in the Asian population, 80% have dense breast tissue, compared to 40% of Americans. Traditional screening techniques are only 48% accurate with dense tissue. The iTBra has an 82% accuracy (against biopsy results, not other screening techniques), comparable to traditional techniques, but also presents results this accurate for dense tissue. Since this result was achieved with a small population, continued refinement of algorithm coupled with additional AI/machine learning and larger sample size should increase the accuracy.
Another reason for using the cloud as a repository: the intellectual property is not available to the referring physician. Only the results are sent to the physician, and the patient is able to upload the data to the cloud from home. This also keeps the physician in the loop. The data is appropriately anonymized and encrypted so only the physician knows the results, and only Cyrcadia knows how it was analyzed, but not the patient’s PII. This bodes well from a privacy perspective – leaving the patient to manage their own personal health data.
Why Cisco?
Why Cisco was a question directed to the Cisco VP at the screening. His answer was that Cisco seeks to be involved in cutting edge IoT, security, and cloud computing, especially machine learning and AI. Through in wearable devices, saving lives, and Cisco was on board. Though it was unknown at the project’s start if clinical success would be achieved, it appears the gamble has paid off for Cisco and Rob Royea.
Tech Republic
By Teena Maddox | May 30, 2017, 10:52 AM
“The product is so groundbreaking that tech giant Cisco is a sponsor of Detected”
The top 3 takeaways for TechRepublic readers
1. Cisco is funding a documentary on the iTBra, which is intended for the early detection of breast cancer.
2. The iTBra is an IoT-connected device that contains 16 sensors that women wear for 2 hours with the resulting data sent automatically to their physicians.
3. The iTBra is based on technology approved in the late 1980s that wasn't feasible until now, with the advent of wearable devices.
Early detection remains the primary defense...etc
Of 1,100,000 women tested 18,000 had invasive breast cancer...etc 1:61
(Above quotes were from articles below, so if you could buy a lottery ticket & have a
1:61 that’s one in sixty one chance to win would you buy the ticket ??? Your damn right you
would... so what’s more important the lottery or your life- yes I think I’ll buy the iTBra...)
Breast Cancer
Updated: Oct 22, 2018
* Author: Pavani Chalasani, MD, MPH; Chief Editor: John V Kiluk
The American Cancer Society estimates that 266,120 new cases of breast cancer will be diagnosed in women in 2018.
Early breast cancers may be asymptomatic, and (Diagnosis of
Breast cancer is often first detected as an abnormality on a mammogram before it is felt by the patient or health care provider) pain discomfort are typically not present. If a lump is discovered, the following may indicate the possible presence of breast cancer.
Screening:
“Early detection remains the primary defense in preventing breast cancer”. Screening modalities include the following:
* Breast self-examination?
* Clinical breast examination?
* Mammography?
* Ultrasonography?
* Magnetic resonance imaging
Breast Cancer Surveillance Consortium (BCSC) Risk Calculator
The Breast Cancer Surveillance Consortium (BCSC) Risk Calculator was developed and validated in 1.1 million women undergoing mammography across the United States, of whom 18,000 were diagnosed with invasive breast cancer. The BCSC Risk Calculator has been externally validated in the Mayo Mammography Health Study. In 2015, the BCSC risk calculator was updated to include benign breast disease diagnoses and to estimate both 5-year and 10-year breast cancer risk.
(So, your hand or iTBra, your hand or iTBra ???, My wife says iTBra...)
Practice Essentials:
Early detection remains the primary way to prevent the development of life-threatening breast cancer. Breast cancers that are detected when smaller or nonpalpable are more treatable and thus are associated with a more favorable prognosis.
Talk about messed up?
(Many expert groups have offered their recommendations for breast cancer screening, and much of the controversy lies in the fact that there is not a consensus about when to begin and end screening, how often to screen, and by what technique. These groups include the following;
* American Cancer Society (ACS)
* American College of Obstetricians and Gynecologists (ACOG)
* American College of Physicians (ACP)
* American College of Radiology (ACR)
* American Medical Association (AMA)
* National Cancer Institute (NCI)
* National Comprehensive Cancer Network (NCCN) has
* United States Preventive Services Task Force (USPSTF)).
(iTBra seems reasonable for little effort)
Save$$$Lives
There a team, 1st broken English many post ago and now
a white southern guy “ Ya all”, with more fluid sentences, pretty obvious.
Could it be AI...ahhhhhhhhhhhh.
Cyrcadia Health -Please check back soon to see our new website. Contact us for more information. More Info
“Principals of these companies (Nerdy Dragon Boise, ID. website reconstruction) have been involved with Cyrcadia Health for a number of years and have a deep understanding of our value proposition to bring ( “significant value to our Go-To-Market LAUNCHES” ), says Matt Benardis, CEO. “Their depth of experience in our markets means...
Love that Plural word-LAUNCHES ,, So bets on website launch before or day of Launch ???
Key words below article:Cyrcadia Health— “Self breast exam in their own home”...$$$. Tic toc
https://tech.co/8-startups-fighting-breast-cancer-2017-10
“Saving lives using AI in the fight against cancer”
Users: Mayo Clinic, Harvard Med School, Yale Med, Centura Health, Brigham& Young Women’s Hospital, Centura Health, Nationwide Children’s, etc
THE WORLD HAS GONE DIGITAL. HAVE YOU?
Built by Pathologists for Pathologists
Deep Lens is extending one of the world’s first digital pathology cloud platforms that for over ten years has allowed pathology groups to collaborate on groundbreaking cancer research across dozens of cancer types.
Based on feedback from hundreds of expert global users, we are enhancing the system to include AI-powered image detection and workflow support, telepathology, collaboration, cloud storage and built in APIs for integration by hardware and software vendors and biopharma companies.
((Sounds familiar Cyrcadia Health & Cyrcadia Asia create cloud based Core Lab division, “Cyrcadia's user base grows, it has the potential to be the world's largest database of breast health and breast cancer incidence and we hope in the near future we can make a major contribution to research, prevention and treatment.
Data obtained from the iTBra is communicated directly to the “Cyrcadia's Core Lab” for analysis via a PC or smartphone app))
Tic toc...
iTBra Focus is finding tumors before they become invasive... this is the primary premise of the device. Women
will ask themselves is my hand more effective or a device that is more effective every month ?
Ask yourself which would you prefer, ask your wife, daughter, friends wife, etc etc & the answers I get are YES
I’ll try it... tic tic tic toc.
Schultz...Schultz..Wrestler has done it again...he is letting the cat out of the bag, soon all women will want
the iTBra (80,000,000million Mammograms plus...per year), we must get Hogan’s men busy mass producing
these life savers...yes Commandeer Clink. (Good find Wrestler, the doorbell will be ringing soon & the Party
starting...!)
Officer shares held that’s public: 342 Million ~11.5% of OS
Louis Keith Trust
160.333 mil shares
Jim Holmes
181.666 mil shares
Louis Keith was a brilliant man, & one of the iTBra founding fathers.
MD PhD Inventor -He was an elected member and/or fellow in many societies, including the Royal Society of Medicine, the Royal Society of Health, the American College of Surgeons and the American College of Obstetricians and Gynecologists.
Interesting: Louis G Keith
Circadian rhythm chaos: A new breast cancer marker
Article· Literature Review in International journal of fertility and women's medicine 46(5):238-47 · September 2001 with 72 Reads
Source: PubMed
Cite this publication
L G Keith
J J Oleszczuk
M Laguens
Abstract
The most disappointing aspect of breast cancer treatment as a public health issue has been the failure of screening to improve mortality figures. Since treatment of late-stage cancer has indeed advanced, mortality can only be decreased by improving the rate of early diagnosis. From the mid-1950s to the mid-1970s, it was expected that thermography would hold the key to breast cancer detection, as surface temperature increases overlying malignant tumors had been demonstrated by thermographic imaging. Unfortunately, detection of the 1-3 degrees C thermal differences failed to bear out its promise in early identification of cancer. In the intervening two-and-a-half decades, three new factors have emerged: it is now apparent that breast cancer has a lengthy genesis; a long-established tumor-even one of a certain minimum size-induces increased arterial/capillary vascularity in its vicinity; and thermal variations that characterize tissue metabolism are circadian ("about 24 hours") in periodicity. This paper reviews the evidence for a connection between disturbances of circadian rhythms and breast cancer. Furthermore, a scheme is proposed in which circadian rhythm "chaos" is taken as a signal of high risk for breast cancer even in the absence of mammographic evidence of neoplasm or a palpable tumor. Recent studies along this line suggest that an abnormal thermal sign, in the light of our present knowledge of breast cancer, is ten times as important an indication as is family history data.
Arnie understood, point being 3 yrs for that mkt to grow...iTBra accepted more today than 3 yrs ago!!! We r fighting an uphill battle.
Interesting to see how 4search.com has Cyrcadia info., i’ve never seen Cyrcadiahealth say “please check back soon to see our new website”.
1. Cyrcadia Health | Early Detection Technology for Breast Cancer
cyrcadiahealth.com
Please check back soon to see our new website. Contact us for more information. More Info
Another great article, right from the Insurance industries mouth. “he points to the iTBra”
Fits right in, no pun intended, with my New Investor post Telemedicine many months ago- the insurance industry R cheerleaders...
https://insurancenewsnet.com/innarticle/‘Wearable-Tech’-Could-Provide-Insurer-Opportunity-a-605244#
Sorry about no link, I was flyin this am...https://globenewswire.com/news-release/2018/08/09/1549619/0/en/Wearable-Medical-Device-Market-Smart-Technology-to-Achieve-USD-27-25-Bn-Revenue-Forecasts-by-2023-Market-Research-Future.html
Cyrcadia Health 2nd LST par
Good Article Disregard if you have read it before
Cyrcadia 2nd last par...tic toc...
Very true mead,, (it almost makes u wonder if they r trying to keep this quiet until product launch / website release / & Reuter’s PR announcement...then Boom, I’ll be very disappointed if it doesn’t roll that way).
Ereleases.com ~ $1000 tot package (web dist.& journalist dist.--AP associated press—PR Newswire network
PR Newswire ~$1200 plus (500 words)
Reuter’s which they’ve used before per below article don’t remember this one:
?@MercyVirtual
https://www.reuters.com/brandfeatures/venture-capital/article?id=14381&pid=
(Wouldn’t post so copy article)!!!
Reuter’s-Powerful Lifesaving Potential with IoT Bra, August 15, 2017:
The Internet of Things (IoT) is changing the way we live. Generally, an IoT device is any type of device that has processing, sensing, and communication capabilities. The IoT can be considered as the currently ongoing evolution of the Internet. Connected devices like our phones, watches, lights, and even televisions are communicating to make our lives better.
However, IoT has an even bigger promise, and it’s about more than convenience. Devices and people are connecting to save lives. Healthcare organizations are connecting doctors to their patients through smart devices remotely in the comfort of their own homes.
Every year, millions of women are diagnosed with breast cancer. And we desperately need a game-changer. 1 in 8 women in the US will develop invasive breast cancer. Every 13 minutes, one woman dies of breast cancer in the US. Every 19 seconds, someone in the world is diagnosed with breast cancer.
Though there have been tremendous advancements in treatment, tens of thousands of women in the U.S. die from this horrible disease. Early detection is critical, a remarkable example of this is a bra that detects breast cancer. The iTBra is a connected bra, which could go to market globally in the first half of 2018, is intended for the early detection of breast cancer.
Feasible with the Emergence of Internet of Things
The iTBra is based on technology approved in the late 1980s that weren’t feasible until now, with the advent of wearable devices. Even though it is feasible with the emergence of IoT, this technology was still a prototype a few years ago. Today, it’s patented and undergoing clinical validation trials and is expected to get approval later this year.
The iTBra was pioneered by scientist and entrepreneur Rob Royea. It’s a wearable smart device that detects temperature changes in breast tissue. This data helps healthcare providers assess the risk of breast cancer, even in women with dense tissue, which is a factor that can often make detection with traditional mammograms difficult.
16 Sensors to Detect Breast Cancer
The iTBra, made by Cyrcadia Health, contains 16 sensors that detect changes in breast tissue. The sensors are contained in a patch that attaches with an adhesive to the patient’s skin. The patient wears the iTBra for 2 hours, and the data collected is sent directly to her physician for analysis. It’s an alternative to the discomfort of a mammogram, and it’s especially helpful for women with dense breast tissue.
Used as a monthly breast screening system, iTBra can provide thousands of women early warnings of cancer formation, enabling doctors to implement treatment plans sooner and ultimately saving lives. The bra works through predictive algorithm approach (artificial intelligence), all processing is accomplished in a cloud based analytic location. The results of the screening are automatically sent to the user.
If the user selects to include the physician data in their application, that physician can get an immediate email to the need for a physician follow-up requested. If the insurance company has financed the garment, they too could be notified with an automated alert of the need for follow-up exam.
Much Earlier Detection for Breast Cancer
The future is exciting. And for cancer patients, full of hope. This is a ground-breaking example of the positive impact the Internet of Thing will have on our healthcare industry. The iTBra is a beacon of hope that solidifies my belief that technology is here to improve our lives and help us overcome some of the world’s greatest challenges, especially in healthcare.
End
Back
Powered By Broaden News ©
Indonesia’s Electronic Signature Startup PrivyID secures US$5 million in Series AMalaysian wealth fund Khazanah to buy Prince Court Medical Centre from PetronasVinaCapital to invest US$10 million in Vietnamese real estate firm RiconsAmazing Advances in Asia’s Military AI and RobotsVTVCab IPO to raise US$262 millionWorld’s Smallest Chip: The Catalyst for IoT by 2020Arriving Shortly: Flying Cabs and Robo-TaxisFilipino unicorn Revolution Precrafted receives US$3.2 billion deal in DubaiSelfie Drones and Smart Suitcases: Will the Ideas Fly?China’s JW Therapeutics raises US$90 million round from Temasek, Sequoia Capital
More NewsPowered By Broaden News ©
For content enquiry, please reach us at
FEATURED NEWS
1Catcha Group to lead seed investment in Wedding Marketplace Hitchbird2Manila Water expands to Indonesia through 20 percent stake acquisition of bulk water supplier STU3An Phat Holdings receives US$15.6 million investment from Valuesystem
CATEGORIES
All News
Economy
Enterprise
Finance
Funding
IPO
Startup
LATEST NEWS >
Skincare Startup Alcheme raises Seed Investment round for Southeast Asia Expansion
Alcheme Skincare, a Singapore-based disruptive skincare company has closed its initial seed funding round led by DSG Consumer Partners.
12:16pm UTC
Myanmar Ride-Hailing Startup Oway raises US$14.7 million for Business Expansion
Investors in Oway’s latest funding round include Daiwa PI Partners, IFC, and NSI ventures.
11:29am UTC
Ballarpur Industries sells Malaysian arm Sabah Forest for US$310 million
04:56am UTC
Catcha Group to lead seed investment in Wedding Marketplace Hitchbird
Hitchbird will use the capital for hiring talent, product development, and marketing.
10:45am UTC
Vertex Ventures to co-lead US$11 million round in Israeli transcription startup Verbit
Verbit uses AI to combine software with human transcribers to improve quality, speed and price of services.
06:29am UTC
Yaro good find...someone has plastered it all over Twitter maybe the Co will get the hint,
Facebook idea good more exposure...
At least Cyrcadia listened to us to take done LLBO website, just going to be interesting to see how the
consolidation goes, if at all?
U know when u look at twitter and followers, one leads to another many top people in journalism, medical, insurance & other related fields, hammer them repost Cyrcadias Asia interview, let them know they all have an interest, pro active marketing for a Co that is not the greatest at it.
Let’s Brand this product, don’t forget to let them know the LLBO stk symbol as well- “”most important””.
3500 B.C. Egyptians have mirrors of metal (1st self breast exam)
No Shorts Here...
Glad LLBO has CLASS 11 clearance....& is now in FDA discussions for the
OTC market Class1 clearance ( imagine walking into Walmart, Walgreens, Cosco, ordering on line
through Elephantzon (Amazon), ahh how easy to buy your life saving device... maybe I’ll buy (2)...an extra
for my sister who Never gets a Mammogram.
Cyrcadia, Inc. – 2017 Year End and 2018 Look Forward Newsletter
by admin | Feb 21, 2018 | News | 0 comments
Regulatory Clearance, Trials Recap
CI’s current US trial success has allowed us to utilize a Non-Filing Justification (NFJ) with the FDA, under our current FDA 510(k) Class II clearance, enabling CI to go to market. Additionally, CI and CA have contracted with two regulatory advisor contractors to drive to a Class I designation (Over the Counter and direct to consumer markets) allowing for entry into market without the scrutiny of a class II device (Clinical, prescribed by physician market), as the iTBra™ stands now. The intent is launch into both the consumer and Over the Counter (OTC) markets almost simultaneously with the clinical markets. Thus far, indications are favorable for this approach and we will be meeting directly with the FDA in the months to come, declaring our intent. We will report again on the meeting outcomes once definitive. Moreover, CI will pursue a Modified 510(k) through the FDA enabling the rapid expansion of the clinical markets. This does not preclude us from going to market with our existing 510(k), Class II clearance (see the NFJ position above), but will certainly enhance our visibility and buy-in from the medical/clinical community.
And to think a company can reach a $450,000,000 Million dollar market cap on foreign sales alone, a life saving
device that has NO FDA clearance (a Sepsis filter for Hospitals, that stock forum posters said would never happen, BUT it DID), yes that ...Co. is “Cytosorbents”...((If only I had bought more shares of it than the $2000 I put into the investment selling it in 2015 four $29,000 I wonder what will happen to the stock price when they get FDA clearance for the US market gives me thoughts of Mount Everest))...OR does it make me salivate over
my several million LLBO shares I hold...ahh yes Amazon.
Glad LLBO has CLASS 11 clearance....& is now in FDA discussions for the
OTC market Class1 clearance ( imagine walking into Walmart, Walgreens, Cosco, ordering on line
through Elephantzon (Amazon), ahh how easy to buy your life saving device... maybe I’ll buy (2)...an extra
for my sister who Never gets a Mammogram.
Cyrcadia, Inc. – 2017 Year End and 2018 Look Forward Newsletter
by admin | Feb 21, 2018 | News | 0 comments
Regulatory Clearance, Trials Recap
CI’s current US trial success has allowed us to utilize a Non-Filing Justification (NFJ) with the FDA, under our current FDA 510(k) Class II clearance, enabling CI to go to market. Additionally, CI and CA have contracted with two regulatory advisor contractors to drive to a Class I designation (Over the Counter and direct to consumer markets) allowing for entry into market without the scrutiny of a class II device (Clinical, prescribed by physician market), as the iTBra™ stands now. The intent is launch into both the consumer and Over the Counter (OTC) markets almost simultaneously with the clinical markets. Thus far, indications are favorable for this approach and we will be meeting directly with the FDA in the months to come, declaring our intent. We will report again on the meeting outcomes once definitive. Moreover, CI will pursue a Modified 510(k) through the FDA enabling the rapid expansion of the clinical markets. This does not preclude us from going to market with our existing 510(k), Class II clearance (see the NFJ position above), but will certainly enhance our visibility and buy-in from the medical/clinical community.
And to think a company can reach a $450,000,000 Million dollar market cap on foreign sales alone, a life saving
device that has NO FDA clearance (a Sepsis filter for Hospitals, that stock forum posters said would never happen, BUT it DID), yes that ...Co. is “Cytosorbents”...((If only I had bought more shares of it than the $2000 I put into the investment selling it in 2015 four $29,000 I wonder what will happen to the stock price when they get FDA clearance for the US market gives me thoughts of Mount Everest))...OR does it make me salivate over
my several million LLBO shares I hold...ahh yes Amazon.
This is is very light bashing, Cytosorbents got the hell knocked “literally “ out of it, before it finally (over 9 yrs) had foreign & NO USA sales & Boom...Market cap exceeded $450 Mil. but I previously posted this...!